Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Core & Main enters the final stretch before its December earnings with short sellers adding modestly and the Street still largely bullish but walking back price targets after a guidance cut that landed badly in September.
Short interest has drifted higher through the autumn, reaching 6% of the free float after a 4.4% build over the past month. The move is steady rather than aggressive: roughly 11.5 million shares short, up from around 11 million at the start of September. The borrow market gives shorts little friction. Cost to borrow is running below 0.41%, down about 14% on the week, and availability is deep at 613%, meaning there are more than six shares available to lend for every one already borrowed. Nothing in the lending market points to squeeze pressure. The options market tells a more bullish story. The put/call ratio at 0.30 is well below its 20-day average of 0.50, and the z-score of -0.83 reflects the lightest demand for downside protection in months. Call positioning dominates, a contrast to the more hedged set-up that prevailed through mid-September.
The analyst community has spent the past four weeks resetting expectations after CNM cut its 2025 adjusted EBITDA guidance to $920 to $940 million, missing a Street consensus of $980 million. The response was a coordinated wave of target reductions on September 10, with Wells Fargo trimming to $48 from $65, Baird to $57 from $66, and Barclays to $61 from $62. Citi, the most cautious, landed at $46. This week RBC Capital's Mike Dahl moved again, cutting to $57 from $60 while keeping his Outperform. The mean target across the coverage group now sits around $55, a 30% premium to the current price of $42.10. The bull case centres on gross margin expansion (up 40 basis points to 26.8%) and 6.6% year-over-year net sales growth. The bear case is the guidance downgrade itself: management blamed softening residential demand and elevated operating costs, and with weak August volumes echoing similar warnings from peers, the Street is no longer willing to give the benefit of the doubt. EPS momentum factor scores remain strong at 93 on the 30-day reading, suggesting analyst estimate revisions have recently turned positive even as targets came in, a small offset to the more cautious direction of travel.
The company's own SEC filings show buyback activity doubled in the most recent quarter. Buyback spend came in at $88 million in Q2, up 126% on the same quarter a year earlier. Remaining buyback authorisation stands at $581 million, up 104% year-on-year. That is a large dry-powder figure for a stock that has fallen roughly 18% year-to-date, and it suggests management views the current price as an opportunity. The alt data layer covers Wikipedia views and EDGAR buyback filings for CNM; neither dataset has been measured or tested as a lead indicator for the company's reported figures, so the buyback data is corporate capital-allocation context rather than a read on the forthcoming December print.
The most notable institutional move in the 13D/G register is Select Equity Group trimming its disclosed position from 5.1% to 4.1%, filed in February, while BlackRock edged up slightly to 10.1%. FMR (Fidelity) added 3.6 million shares in the quarter ending September 30, one of the larger incremental moves among the top holders. No 13D activist is on the register. On insiders, the only open-market purchase logged in recent months was director James Hope buying roughly $95,000 worth of stock in early July at $46.01, a modest but genuine signal given it was a discretionary purchase, not a grant. All other recent insider activity has been compensation-related share withholding, which carries no informational weight.
The last two earnings prints have both produced one-day drops of more than 6%. September's Q2 release sent the stock down 7.3% on the day, recovering partially over five days to end the week down 2.8%. The prior print brought a similar initial hit. With the next report scheduled for December 8, the pattern of negative initial reactions after guidance-sensitive prints is the clearest data point to hold in mind as positioning evolves over the coming weeks.
What to watch: whether the steady short-interest build through September and early October continues into the next reporting cycle, and whether the heavily call-skewed options positioning begins to unwind as December 8 draws closer.
See the live data behind this article on ORTEX.
Open CNM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
